Berenberg Bank upgraded shares of Conduit Pharmaceuticals (NASDAQ:CDT – Free Report) to a strong-buy rating in a research report sent to investors on Friday, Zacks.com reports.
Conduit Pharmaceuticals Stock Down 5.0 %
CDT opened at $0.23 on Friday. Conduit Pharmaceuticals has a twelve month low of $0.21 and a twelve month high of $25.00. The firm’s 50-day simple moving average is $1.49 and its 200-day simple moving average is $2.52.
Conduit Pharmaceuticals (NASDAQ:CDT – Get Free Report) last issued its quarterly earnings data on Tuesday, May 14th. The company reported ($0.05) EPS for the quarter.
Conduit Pharmaceuticals Company Profile
Conduit Pharmaceuticals Inc, a clinical-stage specialty biopharmaceutical company, develops pharmaceutical products that provides unmet medical needs in the areas of autoimmune diseases and idiopathic male infertility. Its pipeline includes AZD1656, which has completed Phase I trials for the treatment of type 2 diabetes, renal transplant, Hashimoto's thyroiditis and Grave's disease, uveitis, and preterm labor; and AZD5904, which has completed Phase I clinical trials for the treatment of idiopathic male infertility.
Featured Stories
- Five stocks we like better than Conduit Pharmaceuticals
- What Makes a Stock a Good Dividend Stock?
- Why This Manufacturer is Committing to a Massive Buyback Program
- 3 Fintech Stocks With Good 2021 Prospects
- Top 2 Cheap Healthcare Stocks to Buy as Sector Outperforms
- P/E Ratio Calculation: How to Assess Stocks
- Healthcare Stock Rides the Acute Services Phenomenon to New Highs
Receive News & Ratings for Conduit Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Conduit Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
